COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS CHEMOTHERAPY VS CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER IN JAPAN

被引：0
|
作者：
Morimoto, K. [1 ]
Moriwaki, K. [2 ]
Shimozuma, K. [3 ]
Nakayama, T. [1 ]
机构：
[1] Kyoto Univ, Kyoto, Japan
[2] Ritsumeikan Univ, Kyoto 26, Japan
[3] Ritsumeikan Univ, Kusatsu, Japan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA7
引用
收藏
页码：S505 / S505
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
    Morimoto, Kosuke
    Moriwaki, Kensuke
    Shimozuma, Kojiro
    Nakayama, Takeo
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (12) : 1188 - 1197
  • [2] Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
    Kosuke Morimoto
    Kensuke Moriwaki
    Kojiro Shimozuma
    Takeo Nakayama
    Journal of Gastroenterology, 2023, 58 : 1188 - 1197
  • [3] Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China
    Chen, Xin-Zu
    Jiang, Kun
    Hu, Jian-Kun
    Zhang, Bo
    Gou, Hong-Feng
    Yang, Kun
    Chen, Zhi-Xin
    Chen, Lia-Ping
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (17) : 2715 - 2722
  • [4] Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China
    Shu, Yamin
    Ding, Yufeng
    Zhang, Qilin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Cao, Xueqiong
    Zhang, Mingming
    Li, Na
    Zheng, Bin
    Liu, Maobai
    Song, Xiaobing
    Cai, Hongfu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [6] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
    Cao, Xueqiong
    Cai, Hongfu
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [7] Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
    Feng, Mingyang
    Chen, Yue
    Yang, Yang
    Li, Qiu
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [8] Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
    Huo, Gengwei
    Liu, Wenjie
    Kang, Shuo
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [9] Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost-effectiveness analysis
    Lang, Yitian
    Lin, Yan
    Li, Dan
    Liu, Jiyong
    Liu, Xiaoyan
    CANCER MEDICINE, 2023, 12 (18): : 18447 - 18459
  • [10] Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
    Liu, Xiaoyan
    Lang, Yitian
    Liao, Yahui
    Zhu, Yizhun
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
12345